Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Type2diabetes
Phase NA
Enrollment 220
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Sulfonylurea medications are unsafe for older patients with diabetes. They are associated not only with hypoglycemia, but also with falls and increased cardiovascular risk. Yet they continue to be prescribed frequently. Indeed, older adults with type 2 diabetes, who are especially prone to adverse effects, are more likely to be prescribed sulfonylureas than younger patients. This is unfortunate since over the past several years, newer, safer, and more effective classes of medications (GLP-1 agonists and SGLT2-inhibitors) have emerged. The investigators acknowledge that sulfonylureas are inexpensive and that their low cost is a driver of continued use. However, the investigators believe patients and providers should have discussions about the risks of sulfonylureas and safer and more effective alternatives, to make diabetes care safer overall in ambulatory settings. Our research is designed to promote such discussions. The investigators will first identify patients taking sulfonylureas regularly. Next, using recommendations from AHRQ and the Canadian Deprescribing Network, the investigators will empower patients to discuss their medications with their providers through a simple question prompt sheet. Patients will be divided into an intervention group which receives explicit prompting questions, and a control group that receives a general brochure on diabetes medications. Health care providers will receive education about newer diabetes medications through case-based discussions and academic detailing. Finally the investigators will measure key outcomes including the proportion of patients who have discussions about sulfonylureas and alternatives, rates of discontinuation, and measures of control of diabetes and associated cardiovascular risks. The investigators will also evaluate the experiences of patients and providers qualitatively through brief, semi-structured interviews. Should our multi-faceted, patient-oriented intervention prove effective in promoting discussions of sulfonylureas and alternatives, and also discontinuation of sulfonylureas and switching to newer alternatives, the investigators will incorporate our prompting questions into routine care for patients taking sulfonylureas. Our intervention can be easily disseminated to other settings and therefore has considerable potential to improve safety among patients with type 2 diabetes nationwide.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Other: Prompt-sheet — Simple prompt sheet with which participants will encouraged to use to guide a conversation with their provider at their next visit for routine diabetes care. These questions are based on recommendations from the Agency for Healthcare Research and Quality's Question Builder App and also on recommendations from the Canadian Deprescribing Network which specifically addresses SU use.
  • Other: Usual education — Control group patients will be sent an information brochure with content from the NIDDK about diabetes medications (https://www.niddk.nih.gov/health-information/diabetes/overview/insulin-medicines-treatments).

Primary Outcomes

  • Proportion of patients who had a conversation with their primary care provider about SU use and alternatives for their diabetes management (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-10-01
Completion: 2027-06-30
Eligibility
Age: 45 Years and older
Sex: ALL
Volunteers: false
Enrollment: 220 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospitals Cleveland Medical Center
Collaborators: American Heart Association
Principal Investigators:
  • Ian Neeland, MD (PRINCIPAL_INVESTIGATOR) - University Hospital Cleveland Medical Center
Contact Information
Study Contact:
Ian Neeland, MD
216-844-5965
ian.neeland@uhhospitals.org
Amanda Davies, MBA
216-844-7635
Amanda.Davies@UHhospitals.org
Ann Dever, RN
2162865038
ann.dever@uhhospitals.org
University Hospitals Cleveland Medical Center
Interventions
  • Other: Prompt-sheet — Simple prompt sheet with which participants will encouraged to use to guide a conversation with their provider at their next visit for routine diabetes care. These questions are based on recommendations from the Agency for Healthcare Research and Quality's Question Builder App and also on recommendations from the Canadian Deprescribing Network which specifically addresses SU use.
  • Other: Usual education — Control group patients will be sent an information brochure with content from the NIDDK about diabetes medications (https://www.niddk.nih.gov/health-information/diabetes/overview/insulin-medicines-treatments).
Study Locations (1 sites)
University Hospitals Cleveland Medical Center, Cleveland, Ohio 44106 United States
Eligibility Criteria
Inclusion Criteria: * Age ≥ 45 years * Type 2 diabetes (diagnosed on or before 12/31/2021) * Current/active prescription for one or more SU medications * Established care (≥2 visits) with UH primary care provider (PCP) since 2021 Exclusion Criteria: * Type 1 diabetes * PCP provides a reason why patient participation is inappropriate (e.g., known cost barriers without any alternatives, prior discussion with patient about alternatives, etc.) * Patient unable or unwilling to have conversation with their PCP regarding SU * Unable to provide informed consent
Conditions Breast Cancer Female
Phase PHASE2
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Female patients undergoing surgical treatment for early breast cancer and meeting the inclusion criteria for adjuvant breast radiotherapy were randomized into two groups. One group will receive adjuvant whole-breast radiotherapy in ultra-hypofractionated regimen of 26 Gy in 5 fractions. In contrast, the other group will receive partial breast irradiation with a dose of 26Gy in 5 fractions. The study's objective is to compare the effects of both breast radiotherapy protocols in terms of locoregional disease control and survival and to compare the adverse effects of radiotherapy between the two protocols. To determine if there is a correlation between different parameters and the efficacy and degree of toxicity for both protocols.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: Ultra-fractionated WBI — An ultra-short course of radiotherapy with 26Gy in 5 fractions will be administered to the whole breast where the tumor was located.
  • Radiation: Ultra-fractionated PBI — An ultra-short course of radiotherapy with 26Gy in 5 fractions will be administered to the part of the breast where the tumor was located.

Primary Outcomes

  • Acute toxicity (1-6 months after RT)
  • Late toxicity (6-60 months after RT)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2023-06-01
Completion: 2033-05-31
Eligibility
Age: 50 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Oncology Institute of Vojvodina
Contact Information
Study Contact:
Olivera Ivanov
0214805496
ivanov.olivera@onk.ns.ac.rs
Marko Bojovic
bojovic.marko@onk.ns.ac.rs
Olivera Ivanov
0214805496
ivanov.olivera@onk.ns.ac.rs
Oncology Institute of Vojvodina
Interventions
  • Radiation: Ultra-fractionated WBI — An ultra-short course of radiotherapy with 26Gy in 5 fractions will be administered to the whole breast where the tumor was located.
  • Radiation: Ultra-fractionated PBI — An ultra-short course of radiotherapy with 26Gy in 5 fractions will be administered to the part of the breast where the tumor was located.
Study Locations (1 sites)
Oncology Institute of Vojvodina, Novi Sad, Vojvodina 21204 Serbia
Eligibility Criteria
Inclusion Criteria: * Breast-conserving surgery * Invasive ductal carcinoma * Age ≥ 50 * Tumor size ≤ 3 cm * R0 resection * Unicentric/unifocal carcinoma or multifocal carcinoma within 2 cm of the primary neoplasm * pN0 (sentinel lymph node biopsy or axillary lymph node dissection performed), N1mi * Hormone receptor status - any * Histological grade G1 or G2 Exclusion Criteria: * Neoadjuvant systemic therapy * TNBC (triple-negative breast cancer) * Extensive intraductal component (EIC) * Lymphovascular invasion (LVI) * associated DCIS \> 2.5 cm in size or high nuclear grade
Conditions Suicide, Suicidal Ideation
Phase NA
Enrollment 1485
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The overall aim of this study is to reduce suicide among sexual and gender diverse youth ages 18-24 years old. This study will compare the effectiveness of two brief suicide prevention interventions that have been adapted for use with this population to use in primary care via telehealth and will recruit youth from primary care clinics in multiple metropolitan areas. The primary study outcome is suicidal ideation. Each clinic will be randomly assigned to deliver one of the two study interventions.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: STAT-PC — STAT-PC is an adapted version of Suicidal Teens Accessing Treatment after an ED Visit (STAT-ED). It is a brief intervention based on motivational interviewing (MI) that focuses on mental health care seeking behavior, problem-solving, and referrals plus brief case management. The intervention will consist of an initial session with the youth focusing on accessing mental health care plus case management calls. The interventionist will also be available to assist with referrals for connection to other services later during the study period as needed for up to three months. The intervention may include contact with the youth's mental health provider to make sure linkages are made.
  • Other: YST-III — YST-III is an adapted version of Youth-Nominated Support Team for Suicidal Adolescents (YST-II). The intervention is a brief intervention originally developed for youth who have been psychiatrically hospitalized due to a suicide attempt or suicidal ideation (SI). Participants will nominate supportive adults (age 18 and older) from their lives who agree to provide ongoing contact and support for up to 3 months. YST-III will include an introductory session with the youth who will nominate their support persons plus referrals for mental health services. The support persons will receive training and support on how to best support their youth partner and then ongoing calls to support them in working with their youth partner for up to 3 months.

Primary Outcomes

  • Change in suicidal ideation as measured by the Adult Suicidal Ideation Questionnaire (ASIQ) (baseline and months 1, 3, 6)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-07-13
Completion: 2027-03
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1485 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Elizabeth Arnold
Collaborators: Patient-Centered Outcomes Research Institute
Principal Investigators:
  • Elizabeth Arnold, PhD (PRINCIPAL_INVESTIGATOR) - University of Kentucky
Contact Information
Study Contact:
Elizabeth Arnold, PhD
859-562-3751
Liz.Arnold@uky.edu
Phillip Schnarrs, PhD
University of Pittsburgh
Lauren Gulbas, PhD
Steve Hicks School of Social Work at the University of Texas at Austin
Interventions
  • Other: STAT-PC — STAT-PC is an adapted version of Suicidal Teens Accessing Treatment after an ED Visit (STAT-ED). It is a brief intervention based on motivational interviewing (MI) that focuses on mental health care seeking behavior, problem-solving, and referrals plus brief case management. The intervention will consist of an initial session with the youth focusing on accessing mental health care plus case management calls. The interventionist will also be available to assist with referrals for connection to other services later during the study period as needed for up to three months. The intervention may include contact with the youth's mental health provider to make sure linkages are made.
  • Other: YST-III — YST-III is an adapted version of Youth-Nominated Support Team for Suicidal Adolescents (YST-II). The intervention is a brief intervention originally developed for youth who have been psychiatrically hospitalized due to a suicide attempt or suicidal ideation (SI). Participants will nominate supportive adults (age 18 and older) from their lives who agree to provide ongoing contact and support for up to 3 months. YST-III will include an introductory session with the youth who will nominate their support persons plus referrals for mental health services. The support persons will receive training and support on how to best support their youth partner and then ongoing calls to support them in working with their youth partner for up to 3 months.
Study Locations (3 sites)
University of Pittsburgh, Pittsburgh, Pennsylvania 15261 United States
Steve Hicks School of Social Work at the University of Texas at Austin, Austin, Texas 78705 United States
University of Texas Southwestern Medical Center, Dallas, Texas 75390 United States
Eligibility Criteria
Inclusion Criteria: * be aged 18-24 at the time of enrollment * not have received mental health services in the past 90 days, excluding medication and case management * English-speaking * screen positive for suicide risk Exclusion Criteria: * are actively suicidal * have a developmental disability that would preclude them from participating in the study intervention * who are impaired due to psychosis, mania, or substance use that would prevent them from providing consent. * Participants will also be excluded at YST-III sites if they are unable to identify a minimum of one support person to participate in the intervention with them
Conditions Triple Negative Breast Neoplasms
Phase PHASE2
Enrollment 220
Locations 20 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to evaluate the efficacity and safety of pembrolizumab and capecitabine on the invasive disease-free survival, in participants who have triple negative breast cancer (TNBC) with residual disease after neoadjuvant chemotherapy associated with pembrolizumab.

Design

Study type: Interventional Phases: Phase2 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Pembrolizumab injection — On Day 1 of each cycle for a total of 9 cycles; intravenous (IV) infusion
  • Drug: Capecitabine tablets — 1250 mg/m² BID, on days 1-14 of each 21-day cycle; 8 cycles Dose reduction at 825 mg/m² BID during radiotherapy if indicated
  • Radiation: Local radiotherapy — Local radiotherapy will be performed as per standard practice if indicated.

Primary Outcomes

  • 2-year Invasive Disease-free survival (iDFS) (2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-03-11
Completion: 2028-08
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 220 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: UNICANCER
Principal Investigators:
  • Delphine LOIRAT, MD PhD (PRINCIPAL_INVESTIGATOR) - Institut Curie Paris
  • Jean-Yves PIERGA, MD (PRINCIPAL_INVESTIGATOR) - Institut Curie Paris
Contact Information
Study Contact:
Telma ROQUE, PhD
+33 (0) 1 80 50 12 92
cappa@unicancer.fr
Sylvie Mijonnet, PhD
+33 (0) 1 44 23 04 65
s-mijonnet@unicancer.fr
Aurélie MOREIRA, MD
Moreira.Aurelie@chu-amiens.fr
CHU Amiens Picardie_Site Sud
Interventions
  • Drug: Pembrolizumab injection — On Day 1 of each cycle for a total of 9 cycles; intravenous (IV) infusion
  • Drug: Capecitabine tablets — 1250 mg/m² BID, on days 1-14 of each 21-day cycle; 8 cycles Dose reduction at 825 mg/m² BID during radiotherapy if indicated
  • Radiation: Local radiotherapy — Local radiotherapy will be performed as per standard practice if indicated.
Study Locations (20 sites)
CHU Amiens Picardie_Site Sud, Amiens, 80054 France
Institut Sainte Catherine, Avignon, 84918 France
Centre Hospitalier de la Côte Basque, Bayonne, 64109 France
CHU Jean Minoz, Besançon, France
Polyclinique Bordeaux Nord Aquitaine, Bordeaux, 33077 France
Centre François Baclesse, Caen, 14000 France
Centre Georges-François Leclerc, Dijon, France
CHD Vendee, La Roche-sur-Yon, France
Centre Oscar Lambret, Lille, France
Centre Léon Bérard, Lyon, 69008 France
Eligibility Criteria
• CRITERIA FOR EXPERIMENTAL ARM : Inclusion criteria (for experimental arm): Patients eligible for this study must meet ALL of the following criteria: 1. Patient must have signed a written informed consent prior to any trial specific procedures. When the patient is physically unable to give their written consent, a trusted person of their choice, independent from the investigator or the sponsor, can confirm in writing the patient's consent; 2. Subject ≥18 years of age on day of signing informed consent form (ICF); 3. Histologically proven TNBC defined as follows: 1. HER2 negativity (ASCO/CAP criteria) 2. AND less than 10% of cells stained by immunohistochemistry (IHC) for ER and PgR; 4. TNBC patients previously treated by standard neoadjuvant chemotherapy with a minimum of 6 cycles of immunochemotherapy containing pembrolizumab, per standard of care (and pembrolizumab label) and anthracyclines and/or taxanes (with/without carboplatin). Other drugs may be acceptable following discussion with the sponsor (with the exclusion of capecitabine); 5. Complete resection of the breast tumor(s) (and of any invaded lymph node); 6. No complete pathological response, defined as RCB Class I, II or III (per local assessment); 7. Available representative formalin-fixed paraffin-embedded (FFPE) tumor block from surgery specimen with its histological report; 8. Eastern Cooperative Oncology Group (ECOG) Performance Status \<2; 9. Adequate organ and bone marrow function. All screening lab tests should be performed within 28 days before inclusion; 10. Resolution to at least grade 1 of all acute toxicities from previous therapies including immune-related toxicity due to pembrolizumab, except alopecia and grade 2 immune-related endocrinopathies controlled by hormone replacement which are allowed; 11. Minimal/maximal period for prior treatments (i.e. minimal delay from last dose of prior treatment to C1D1): breast surgery (the wound must have healed prior to C1D1) ≥2 weeks (maximum 10 weeks); last pembrolizumab injection ≥3 weeks; 12. Women of child-bearing potential must have a negative serum pregnancy test within 7 days before C1D1; 13. Women of child-bearing potential and male patients must agree to use 1 effective form of contraception from the time of the negative pregnancy test up to 6 months after the last dose of study drugs; 14. Patient should be able and willing to comply with study visits and procedures as per protocol; 15. Patients must be affiliated to a Social Security System (or equivalent). Non-inclusion criteria (for experimental arm): Patients eligible for this study must not meet ANY of the following criteria: 1. Radiological or clinical evidence of metastatic disease documented by imaging or clinical examination performed during screening period; 2. Has received capecitabine or other ICI than pembrolizumab in the NAC regimen; 3. Has a known additional malignancy, excepted skin basal cell carcinoma, squamous cell carcinoma of the skin, or in situ cervical cancer or previously treated malignancy with no evidence of disease for ≥2 years; 4. Presents a contraindication to continue pembrolizumab treatment as per respective SmPC including known hypersensitivity; 5. Previous immune-related adverse event of any grade due to pembrolizumab that led to permanent discontinuation of pembrolizumab; 6. Presents a contraindication to capecitabine treatment as per SmPC (See EMA website for most recent edition of SmPC); 7. Complete DPD (Dihydropyrimidine Dehydrogenase) deficiency (a systematic screening of DPD deficiency must be performed); 8. Patient with active infection ; 9. Patients with history of uncontrolled or symptomatic cardiac disease ; 10. Patients having received brivudine within 4 weeks prior to inclusion; 11. Require the use of one of the following forbidden treatments during the study treatment period: * Any investigational anticancer therapy other than the protocol specified treatment; * Any concurrent chemotherapy, immunotherapy, biologic for cancer treatment, other than the ones stated in the protocol; 12. Pregnant women or women who are breast-feeding; 13. Patients unwilling or unable to comply with the medical follow-up required by the trial because of geographic, familial, social, or psychological reasons; 14. Persons deprived of their liberty or under protective custody or guardianship; 15. Participation in another therapeutic trial within the 30 days prior to randomization. * CRITERIA FOR STANDARD OF CARE TREATED EXTERNAL COHORT Inclusion criteria (for standard of care treated external cohort) : Patients eligible for this cohort must meet ALL of the following criteria: 1. Patient information prior to study entry and non-opposition to data collection 2. Subject ≥18 years of age ; 3. Histologically proven TNBC defined as follows: 1. HER2 negativity (ASCO/CAP criteria) 2. AND less than 10% of cells stained by immunohistochemistry (IHC) for ER and PgR; 4. TNBC patients previously treated by standard neoadjuvant chemotherapy with a minimum of 6 cycles of immunochemotherapy containing pembrolizumab, per standard of care (and pembrolizumab label) and anthracyclines and/or taxanes (with/without carboplatin). Other drugs may be acceptable following discussion with the sponsor (with the exclusion of capecitabine); 5. Complete resection of the breast tumor(s) (and of any invaded lymph node); 6. No complete pathological response, defined as RCB Class I, II or III (per local assessment); 7. Patient should have received at least one injection of pembrolizumab as post-surgery treatment (concomitantly or after radiotherapy). Non-exclusion criteria (for standard of care treated external cohort) : Patients eligible for this study must not meet ANY of the following criteria: 1. Radiological or clinical evidence of metastatic disease documented by imaging or clinical examination after surgery. 2. Has received capecitabine or other ICI than pembrolizumab in the NAC regimen; 3. Has a known additional malignancy, excepted skin basal cell carcinoma, squamous cell carcinoma of the skin, or in situ cervical cancer or previously treated malignancy with no evidence of disease for ≥2 years; 4. Any investigational anticancer therapy (chemotherapy, immunotherapy, biologic for cancer treatment) other than pembrolizumab only as adjuvant treatment.
Conditions Cough, Asthma, Chronic Obstructive Pulmo...
Phase NA
Enrollment 300
Locations 8 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical study is to validate C-mo System's ability to automatically detect and characterise cough, in patients over 2 years old with cough as a key or refractory symptom. The main questions it aims to answer are: 1. Can C-mo System detect cough events? (automatic cough detection) 2. Can C-mo System characterise cough events? (calculation of cough intensity, identification of cough type and presence of wheeze in detected coughs) Participants will be asked to: * Wear the C-mo Wearable device for 24 hours (1 day); * Complete a diary with relevant activities throughout the monitoring period; * Fill-out questionnaires related to coughing frequency and intensity, usability of the device, and impact of cough on quality of life.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Device: C-mo System — Patients will use C-mo System for a period of 24h, to assess cough characteristics.

Primary Outcomes

  • Cough detection (precision and recall) (24 hours)
  • Cough detection (F1-score) (24 hours)
  • Cough characterisation (precision, recall and global accuracy) (24 hours)
  • Cough characterisation (F1-score) (24 hours)
  • Cough characterisation (Matthews correlation coefficient) (24 hours)
  • Cough characterisation (Cohen's Kappa) (24 hours)
  • Wheezing detection (precision, recall, true negative rate, accuracy, and negative predictive value) (24 hours)
  • Wheezing detection (F1-score) (24 hours)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-12-11
Completion: 2026-09
Eligibility
Age: 2 Years and older
Sex: ALL
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Cough Monitoring Medical Solutions
Collaborators: Universidade Nova de Lisboa
Principal Investigators:
  • Nuno M Neuparth, PhD (PRINCIPAL_INVESTIGATOR) - NOVA Medical School | Faculdade de Ciências Médicas da Universidade Nova de Lisboa
Contact Information
Study Contact:
Diogo B Tecelão, MSc
+351 917 935 447
diogo.tecelao@c-mo.solutions
Sara B Lobo
+351 967 889 091
sara.lobo@c-mo.solutions
Daniela Rodrigues
HPAV - Trofa Saúde Hospital de Alfena
Interventions
  • Device: C-mo System — Patients will use C-mo System for a period of 24h, to assess cough characteristics.
Study Locations (8 sites)
HPAV - Trofa Saúde Hospital de Alfena, Alfena, Portugal
HFF - Hospital Professor Doutor Fernando Fonseca, Amadora, Portugal
Lab3R - Laboratório de Investigação e Reabilitação Respiratória da Escola Superior de Saúde da Universidade de Aveiro, Aveiro, Portugal
CHUC - Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
HDE - Hospital Dona Estefânia, Lisbon, Portugal
NMS Research - Laboratório de Exploração Funcional | Fisiopatologia, Lisbon, Portugal
CHUSJ - Centro Hospitalar Universitário de São João, Porto, Portugal
ICUFP - Instituto CUF Porto, Porto, Portugal
Eligibility Criteria
Inclusion Criteria: * Patients aged 2 years or older; * Patients with symptoms/complaints of cough; * Signed Informed Consent (age ≥ 18 years), signed Informed Consent from the parents/legal representative and the patient (16 and 17 years), or signed Informed Assent and Consent (5 years ≤ age ≤ 15 years). Exclusion Criteria: * Presence of musculoskeletal (e.g., severe scoliosis), neurological (e.g., post stroke), cardiac (e.g., unstable angina), cognitive (e.g., dementia) changes, or other significant conditions that hinder the participants from collaborating in the collection of data. * Damaged/weakened skin at the C-mo wearable device's placement area (epigastric region). * Absence of Informed Consent and/or Assent, as applicable.
Conditions Breast Cancer Invasive
Phase PHASE3
Enrollment 488
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a prospective, randomised, controlled, multicentre study to compare the efficacy and safety between continuous or intermittent extension of adjuvant pyrotinib in invasive human epidermal growth factor receptor 2 (HER2)-positive breast cancer.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Drug: pyrotinib — an irreversible anti-HER2 tyrosine kinase inhibitor

Primary Outcomes

  • Invasive Disease-free Survival (iDFS) (From randomization until time of event up to 2 years.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2023-06-01
Completion: 2030-08
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 488 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: RenJi Hospital
Principal Investigators:
  • Wenjin Yin, M.D. (PRINCIPAL_INVESTIGATOR) - Renji Hospital, School of Medicine, Shanghai Jiao Tong University.
Contact Information
Study Contact:
Wenjin Yin, M.D.
86(21)58852345
yinwenjin@renji.com
Qi Lu
86(21)68383364
rjllb3364@163.com
Wenjin Yin
86(21)68385569
yinwenjin@renji.com
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Interventions
  • Drug: pyrotinib — an irreversible anti-HER2 tyrosine kinase inhibitor
Study Locations (1 sites)
Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127 China
Eligibility Criteria
Inclusion Criteria: * Aged ≥18; * Histologically confirmed invasive HER2 positive breast cancer; * Duration from random time to the last use of trastuzumab or T-DM1 ≤3 years; * Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-1; * Adequate organ functions. Exclusion Criteria: * Metastatic disease (Stage IV); * Gross residual disease remaining after mastectomy or positive margins after breast-conserving surgery; * Subjects that are unable to swallow tablets, or dysfunction of gastrointestinal absorption; * Treated or treating with anti-HER2 tyrosine kinase inhibitor; * Less than 4 weeks from the last clinical trial; * History of immunodeficiency, including HIV-positive, suffering from other acquired, congenital immunodeficiency disease, or history of organ transplantation; * Female patients who are pregnancy, lactation or women who are of childbearing potential tested positive in baseline pregnancy test; Female patients of childbearing age that are reluctant to take effective contraceptive measures throughout the trial period; * Evidence of significant medical illness that in the investigator's judgment will substantially increase the risk associated with the subject's participation in and completion of the study.
Conditions Depressive Symptoms, Anxiety
Phase NA
Enrollment 85
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Sexual minority stressors (e.g., sexual minority identity-based discrimination) contribute to greater risk for and severity of depression, anxiety, substance use disorders and suicide among sexual minority Veterans. However, no brief, scalable, one-on-one interventions targeting sexual minority stressor-related distress are available in Veterans Affairs (VA) for sexual minority Veterans. The proposed research will examine the feasibility, acceptability, and preliminary effectiveness of a brief, 3-session expressive writing intervention to target distress related to sexual minority stressor exposure among sexual minority Veterans. The results of this work will advance knowledge about a promising brief and easy to implement intervention focused on reducing depressive and anxiety symptoms among sexual minority Veterans. This proposal aligns with VA's and CSR\&D's commitment to providing equitable services to sexual minority Veterans and the aim of reducing health disparities among underserved Veteran groups.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Expressive Writing on Minority Stressors — The EWMS protocol will consist of 3 sessions delivered by a therapist (either in-person or remotely via telehealth platform) to sexual minority Veterans. The intervention will begin with an overview of the intervention, brief psychoeducation about expressive writing, and a review of the potential benefits of expressive writing. The initial session will also consist of psychoeducation on sexual minority stressors and common reactions to these stressors (i.e., universal stress reactions and minority-identity specific reactions) and how this relates to psychological outcomes, such as depression and anxiety, and high-risk behaviors, such as substance use and suicidal ideation. The initial session will be 60 minutes (introduction, psychoeducation, and first writing exercise) and the following two sessions (feedback, writing exercises, and check-ins) will take approximately 40 minutes.
  • Behavioral: Neutral Writing — To be comparable to EWMS, the control intervention will also be a 3-session individual intervention involving engaging in a writing exercise per session. For the control writing exercises, participants will be asked to write for 30 minutes about their daily activities since waking up that day based on Pennebaker's standard writing paradigm (Pennebaker \& Beall, 1987). Individuals in the control condition will also be given information about the purpose of the writing exercises to be comparable to the psychoeducation information provided in EWMS. Similar to EWMS, the clinician will check in with the participant about the writing session, such as asking how the session went and how it felt to do the writing, following the 30 minutes of writing.

Primary Outcomes

  • Feasibility of the Expressive Writing on Minority Stressors (EWMS) intervention (This will be assessed through study completion at the end of Phase II of the Study (i.e., end of the 4th year))
  • Patient satisfaction with the Expressive Writing on Minority Stressors (EWMS) intervention (Veterans will complete the Client Satisfaction Questionnaire at the post-treatment (3-4 weeks after beginning treatment) assessment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-03-20
Completion: 2028-09-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 85 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: VA Office of Research and Development
Principal Investigators:
  • Kelly L Harper, PhD (PRINCIPAL_INVESTIGATOR) - VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
Contact Information
Study Contact:
Kelly L Harper, PhD
(857) 364-4417
kelly.harper@va.gov
Brian P Marx, PhD
(857) 364-6071
brian.marx@va.gov
Kelly L Harper, PhD
857-364-4417
kelly.harper@va.gov
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
Interventions
  • Behavioral: Expressive Writing on Minority Stressors — The EWMS protocol will consist of 3 sessions delivered by a therapist (either in-person or remotely via telehealth platform) to sexual minority Veterans. The intervention will begin with an overview of the intervention, brief psychoeducation about expressive writing, and a review of the potential benefits of expressive writing. The initial session will also consist of psychoeducation on sexual minority stressors and common reactions to these stressors (i.e., universal stress reactions and minority-identity specific reactions) and how this relates to psychological outcomes, such as depression and anxiety, and high-risk behaviors, such as substance use and suicidal ideation. The initial session will be 60 minutes (introduction, psychoeducation, and first writing exercise) and the following two sessions (feedback, writing exercises, and check-ins) will take approximately 40 minutes.
  • Behavioral: Neutral Writing — To be comparable to EWMS, the control intervention will also be a 3-session individual intervention involving engaging in a writing exercise per session. For the control writing exercises, participants will be asked to write for 30 minutes about their daily activities since waking up that day based on Pennebaker's standard writing paradigm (Pennebaker \& Beall, 1987). Individuals in the control condition will also be given information about the purpose of the writing exercises to be comparable to the psychoeducation information provided in EWMS. Similar to EWMS, the clinician will check in with the participant about the writing session, such as asking how the session went and how it felt to do the writing, following the 30 minutes of writing.
Study Locations (1 sites)
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts 02130-4817 United States
Eligibility Criteria
Inclusion Criteria: Participants will be Veterans who: * identify as a sexual minority (i.e., identify as gay, lesbian, bisexual, pansexual, queer, or another identity other than heterosexual) * endorse clinically significant depressive or anxiety symptoms (score above 10 on the PHQ-9 or GAD-7) * report a history of sexuality-based minority stressor exposure that is contributing to distress on phone screening * be stable on psychotropic medication for at least 4 weeks if on a psychotropic medication Exclusion Criteria: The exclusion criteria for Veterans in this study are: * clear and current suicidal plan and/or intent (assessed via the Columbia Suicide Severity Rating Scale) * current presentation of unstable mania and/or psychosis (assessed via the Structured Interview for DSM-5) * current substance use disorder, severe (assessed via the Structured Interview for DSM-5) * significant cognitive impairment, including evidence of moderate or severe traumatic brain injury, determined by an inability to comprehend baseline screening questionnaires
Conditions Depression in Old Age, Fragility Fractur...
Phase PHASE4
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this pilot study is to learn about the feasibility about prescribing anti-depressants at discharge in patients aged 50 years and older with a lower extremity fragility fracture. The main questions it aims to answer are: * What are the obstacles to enrolling patients and prescribing anti-depressants among older adults? * Is it possible to start prescribing SNRI medication upon discharge? * What is the prevalence of depressive symptoms amongst patients with different types of injuries and weightbearing status? * What is a transition of care plan for patients who have geriatric depression and require further care? Participants will: * Undergo screening using the Geriatric Depression Scale * Start on Duloxetine 30mg daily at time of discharge * Report medication compliance and complete re-screening monthly * Complete patient reported outcome measures and 3 months, 6 months, and 1 year * Receive a referral to behavioral health, primary care, or psychiatrist for evaluation if they screen positive at any timepoint

Design

Study type: Interventional Phases: Phase4 Allocation: Intervention model: Single Group Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Drug: Duloxetine 30 mg — Duloxetine 30mg daily prescribed at discharge

Primary Outcomes

  • Geriatric Depression Scale (Short Form) Scores (Baseline)
  • Geriatric Depression Scale (Short Form) Scores (up to 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2024-04-08
Completion: 2028-12
Eligibility
Age: 65 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Wake Forest University Health Sciences
Principal Investigators:
  • Rachel Seymour, PhD (PRINCIPAL_INVESTIGATOR) - Wake Forest University Health Sciences
Contact Information
Study Contact:
Erica Grochowski, MPH
704-403-4980
Erica.Grochowski@advocatehealth.org
Erica, MPH
704-403-4980
Erica.Grochowski@atriumhealth.org
Wake Forest University Health Sciences
Rachel Seymour, PhD
Wake Forest University Health Sciences
Interventions
  • Drug: Duloxetine 30 mg — Duloxetine 30mg daily prescribed at discharge
Study Locations (1 sites)
Wake Forest University Health Sciences, Winston-Salem, North Carolina 27157 United States
Eligibility Criteria
Inclusion Criteria: * Geriatric (greater than or equal to 65 years old) * Lower extremity fragility fractures managed operatively Exclusion Criteria: * Polytrauma * Pathological fractures * Patients on hospice * Patients with previously diagnosed psychiatric disorders * Patients with previously diagnosed dementia * Patients already taking Selective serotonin reuptake inhibitors (SSRI)s and Serotonin- norepinephrine reuptake inhibitors (SNRI)s * Patients already taking mood stabilizing medication * Unable to provide informed consent (no use of a legal authorized representative) * Patients with pre-existing life limiting diagnoses (cancer, etc.)
Conditions Metastatic Breast Cancer, Triple Negativ...
Phase PHASE2
Enrollment 168
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a randomized Phase II study of standard of care (SOC) chemotherapy monotherapy vs. SOC chemotherapy combined with tocilizumab biosimilar in Black and non-Black patients with metastatic triple negative and ER-positive, HER2-negative breast cancer.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: SOC Chemotherapy — SOC Chemotherapy will be given AUC 6 IV q3 weeks for a maximum of 9 infusions.
  • Drug: Tocilizumab/Tocilizumab Biosimilar — Tocilizimab/Tocilizumab Biosimilar 8 mg/ actual body weight in kg IV q4 weeks

Primary Outcomes

  • Overall response rate (through study completion (i.e. up to 2 years))
  • Efficacy of tocilizumab biosimilar in Black and non-Black patients (through study completion (i.e. up to 2 years))
  • Progression-free survival (through study completion (i.e. up to 2 years))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-07-02
Completion: 2027-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 168 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Kathy Miller
Collaborators: Genentech, Inc., Breast Cancer Research Foundation, Susan G. Komen Breast Cancer Foundation
Principal Investigators:
  • Kathy Miller, MD (PRINCIPAL_INVESTIGATOR) - Indiana University
Contact Information
Study Contact:
Xin Bryan, RN
317-274-5495
zhongx@iupui.edu
Carlos Aguilera, BA
404-778-1868
winshipcto@emory.edu
Emory University
Shipra Gandhi, MD
Emory University
Interventions
  • Drug: SOC Chemotherapy — SOC Chemotherapy will be given AUC 6 IV q3 weeks for a maximum of 9 infusions.
  • Drug: Tocilizumab/Tocilizumab Biosimilar — Tocilizimab/Tocilizumab Biosimilar 8 mg/ actual body weight in kg IV q4 weeks
Study Locations (7 sites)
Emory University, Atlanta, Georgia 30322 United States
IU Health Joe and Shelly Schwarz Cancer Center, Carmel, Indiana 46032 United States
Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana 46202 United States
Sidney and Lois Eskenazi Hospital, Indianapolis, Indiana 46202 United States
University of Kentucky-Lexington, Lexington, Kentucky 40506 United States
Roswell Park Comprehensive Cancer Center, Buffalo, New York 14203 United States
Duke University, Durham, North Carolina 27708 United States
Eligibility Criteria
Inclusion Criteria: 1. ≥ 18 years old at the time of informed consent 2. Ability to provide written informed consent and HIPAA authorization 3. Locally recurrent (not amenable to local therapy with curative intent) or metastatic breast cancer that is triple negative or ER-positive (ER and PR ≤ 1% weak staining) 4. For patients with TNBC 1. Received up to 2 prior therapies for metastatic disease 2. Prior (neo)adjuvant chemotherapy will be considered one line of therapy for metastatic disease in patients who recur while on or within 12 months of completion of (neo)adjuvant therapy. 3. Patients with TNBC whose tumors are PD-L1+ (CPS \> 10) must have had prior exposure to an immune checkpoint inhibitor in the metastatic setting. 4. Patients who received (neo)adjuvant IO therapy and progress while on or within 12 months of completion of (neo)adjuvant IO therapy may participate without additional IO treatment. 5. Patients with major contraindications to immune therapy, may participate without IO exposure regardless of PD-L1 status in the first line setting. 6. PD-L1 status is not required for patients beyond the first line setting. 7. Participation in this protocol as either first, second and third-line therapy is allowed 5. For patients with ER- positive, HER2-negative breast cancer 1. Must have received prior hormone therapy + CDKi in the adjuvant or metastatic setting. There is no limit on the number of prior hormone therapy regimens. 2. May have received up to 3 prior chemotherapies for metastatic disease. 3. Prior (neo)adjuvant chemotherapy will be considered one line of therapy for metastatic disease in patients who recur while on or within 12 months of completion of (neo)adjuvant therapy. 4. Participation in this protocol as either first, second, third, or fourth-line therapy is allowed 6. Planned standard of care chemotherapy based on NCCN guidelines. 1. Single agent therapy is preferred but use of combination regimens considered SOC by NCCN is allowed. 2. Chemotherapy delivered via a SOC antibody-drug conjugate is allowed but ADCs may not be used in combination with other chemotherapy agents. 7. Measurable disease based on RECIST 1.1 criteria. 8. ECOG PS 0 or 1 9. Patients with treated, asymptomatic CNS disease may participate if the patient is \> 4 weeks from completion of CNS therapy (radiation and/or surgery), is clinically stable at the time of study entry, and is receiving stable or decreasing dose of corticosteroids. Brain MRI or head CT is required at screening for patients with known brain metastases. 10. Adequate organ function as indicated by: 1. Total bilirubin \< ULN (except in patients with documented Gilbert's disease, who must have a total bilirubin \< 3.0 mg/dL) 2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 5.0 x ULN 3. Creatinine clearance of \> 50 mL/min using the Cockcroft-Gault formula 4. Absolute neutrophil count (ANC) \> 1.2 K/mm3 5. Platelets \> 75 K/ mm3 6. Hgb \> 9.0 g/dL 11. Women of childbearing potential must have a negative pregnancy test within 14 days of protocol registration. Women are considered to have childbearing potential (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) unless they meet one of the following criteria: 1. Has undergone a hysterectomy or bilateral oophorectomy; or 2. Has been naturally amenorrheic for at least 24 consecutive months. 12. Women of childbearing potential and men must agree to use effective contraception throughout the study and for 6 months after the last study treatment. NOTE: Acceptable methods of birth control include abstinence, partner with previous vasectomy, placement of an intrauterine device (IUD), condom with spermicidal foam/gel/film/cream/suppository, diaphragm or cervical vault cap, or hormonal birth control (pills or injections). Exclusion Criteria: 1. Prior treatment with or known contraindication to treatment with tocilizumab biosimilar or other IL-6/IL-6R targeted agent 2. Active infection requiring parenteral antibiotics 3. Concurrent use of methotrexate or systemic corticosteroids other than stable or decreasing doses for management of CNS involvement 4. Active or symptomatic CNS disease 5. Patients with HER2+ disease Note: HER2 will be considered positive if scored 3+ by immunohistochemistry (IHC) or 2+ by IHC associated with a fluorescence in situ hybridization (FISH) ratio of \> 2.0 or \> 6 total HER2 gene copies per cell. 6. Patients with active malignancy other than breast cancer. Patients with prior malignancies without recurrence after standard treatment will not be excluded 7. Radiation therapy within 2 weeks of registration 8. Hormone therapy within 2 weeks of registration 9. Planned treatment with Olaparib or other PARP inhibitor.
Conditions AF - Atrial Fibrillation, HTN-Hypertensi...
Phase NA
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The close relationship between the increase of sympathetic tension, AF, and HTN cannot be ignored. In addition, the significant failure rate of PVI (20-50%) in the treatment of AF makes it very necessary to explore the effect of RDN on AF. Therefore, this study aims to compare the effects and safety of PVI alone and PVI combined with RDN with AF combined with HTN, which will open a new chapter for PVI combined with RDN in the treatment of AF.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: Renal Denervation operation — RDN: Percutaneous renal artery sympathetic radiofrequency ablation for both sides. For each side, a total of 13 targets were ablated. The ablation power was 8W\~12W for 40 seconds
  • Other: Pulmonary vein isolation — PVI: Pulmonary vein isolation was performed until the potential of each pulmonary vein disappeared under the guidance of the CARTO mapping system. Ablation of the top line and the bottom line of the left atrium was performed at the same time.

Primary Outcomes

  • Malignant end point event 1 (within 2 years post operation)
  • Malignant end point event 2 (within 2 years post operation)
  • Malignant end point event 3 (within 2 years post operation)
  • Malignant end point event 4 (within 2 years post operation)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-09-01
Completion: 2028-04-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The First Affiliated Hospital of Xiamen University
Contact Information
Study Contact:
Ziguan Zhang
+8618750227289
116504153@qq.com
the first affiliated hopital of Xiamen University
Interventions
  • Other: Renal Denervation operation — RDN: Percutaneous renal artery sympathetic radiofrequency ablation for both sides. For each side, a total of 13 targets were ablated. The ablation power was 8W\~12W for 40 seconds
  • Other: Pulmonary vein isolation — PVI: Pulmonary vein isolation was performed until the potential of each pulmonary vein disappeared under the guidance of the CARTO mapping system. Ablation of the top line and the bottom line of the left atrium was performed at the same time.
Study Locations (1 sites)
the first affiliated hopital of Xiamen University, Xiamen, Fujian 361003 China
Eligibility Criteria
Inclusion Criteria: * 18\<age\<75years * clinic blood pressure≥140/90mmHg or 24-hour ambulatory blood pressure monitoring average blood pressure ≥135/85mmHg * Ecg diagnosis of atrial fibrillation ; * who signed informed consent and were approved by the Ethics Committee of the First Affiliated Hospital of Xiamen University. Exclusion Criteria: * pregnant women or lactating patients; * Patients who were unsuitable for ablation before surgery (unilateral or bilateral renal artery shape and structure were found: renal artery stenosis exceeding 50%, renal aneurysm, previous renal artery interventional surgery, renal artery malformation, renal artery diameter \< 4mm or length of treatable segment \< 20mm) * Patients who only have one kidney or have a history of kidney transplantation * Patients with a history of renal arterial intervention or renal denervation * identified secondary hypertension or Pseudo hypertension except for renal parenchymal hypertension; * malignant tumors or end-stage diseases; * Severe peripheral vascular disease, abdominal aortic aneurysm * whose left atrium is larger than 55mm * obvious bleeding tendency and blood system diseases; * Severe peripheral vascular disease, abdominal aortic aneurysm; * A history of the acute coronary syndrome within two weeks; * acute or severe systemic infection; * drug or alcohol dependence or refusal to sign informed consent. * Other conditions that are not suitable for PVI and RDN
Conditions Pulmonary Arterial Hypertension PAH
Phase PHASE1
Enrollment 96
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Background: A number of diseases can cause a type of lung injury called pulmonary arterial hypertension (PAH). Most people who develop PAH do not survive more than a few years. A new study drug (ZMA001) may help. ZMA001 is a monoclonal antibody. This type of drug consists of proteins, made in a facility, that are very similar to proteins in a human body. But before giving ZMA001 to people sick with PAH, researchers want to find out how the drug affects healthy people. Objective: To test a drug (ZMA001) in healthy volunteers. Eligibility: Healthy adults aged 18 to 60 years. Design: Participants will be screened. They will have a physical exam with blood tests. They will have a urine test for drug use. They will have a test of their heart function. Participants will come to the clinic for 1 inpatient visit of up to 48 hours. ZMA001 is a liquid administered through a tube attached to a needle inserted into a vein in the arm. Participants will receive this drug only once, during their inpatient stay. Some participants will receive the drug; others will receive a placebo in Cohort 1 only. A placebo is a treatment that looks just like the real drug but contains no medicine. Participants will not know which treatment they are getting in Cohort 1. Cohorts 2-4 will receive a single dose of the study drug, administered through a tube attached to a needle inserted into a vein in the arm. After a screening visit, participants will have 1 inpatient visit and up to 8 outpatient visits over 16 weeks after receiving the treatment. Blood draws and other tests will be repeated. Each outpatient visit is approximately 2 hours long. This study is the first time ZMA001 will be administered to people.

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Other: Placebo Cohort 1 (1.5 mg/kg/dose) only — 30mg/ml Sucrose
  • Drug: ZMA001 (BC-NKA-20008) — ZMA001 is a fully human, monoclonal antibody (IgG1) that inhibits migration of activated monocytes and macrophages and reduces pulmonary vascular remodeling and pulmonary artery pressure in pre-clinical rodent models of pulmonary arterial hypertension (PAH).

Primary Outcomes

  • Safety and tolerability of ZMA001 in healthy subjects (day 113)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2023-11-27
Completion: 2027-11-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 96 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Collaborators: Zymedi, Co., Ltd.
Principal Investigators:
  • Jason M Elinoff, M.D. (PRINCIPAL_INVESTIGATOR) - National Heart, Lung, and Blood Institute (NHLBI)
Contact Information
Study Contact:
Sandra Cooper Bennett, R.N.
(240) 328-0465
sandra.cooper@nih.gov
Jason M Elinoff, M.D.
(301) 402-4846
elinoffj@mail.nih.gov
NIH Clinical Center Office of Patient Recruitment (OPR)
800-411-1222
ccopr@nih.gov
National Institutes of Health Clinical Center
Interventions
  • Other: Placebo Cohort 1 (1.5 mg/kg/dose) only — 30mg/ml Sucrose
  • Drug: ZMA001 (BC-NKA-20008) — ZMA001 is a fully human, monoclonal antibody (IgG1) that inhibits migration of activated monocytes and macrophages and reduces pulmonary vascular remodeling and pulmonary artery pressure in pre-clinical rodent models of pulmonary arterial hypertension (PAH).
Study Locations (1 sites)
National Institutes of Health Clinical Center, Bethesda, Maryland 20892 United States
Eligibility Criteria
* INCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. Stated willingness to comply with all study procedures and availability for the duration of the study 2. Male\* or female, aged 18 to 60 years, inclusive 3. In good general health as evidenced by medical history 4. Females of childbearing potential agree to use an accepted method of contraception (see below) throughout study participation and for 120 days after study drug infusion. 5. Males sexually active with a female partner must agree to use a condom with spermicide for 120 days after study drug infusion or be surgically sterile for at least 90 days before screening. Males must also agree to not donate sperm for 120 days after study drug administration. 6. Agreement to adhere to Lifestyle Considerations throughout study duration 7. Ability of subject to understand and the willingness to sign a written informed consent document. * Enrollment of healthy male subjects will be limited to no more than 14 out of the total study cohort of 32 in order to ensure an adequate representation of female subjects. Accepted methods of contraception for females of childbearing potential: * Use of an implanted or intrauterine hormonal device for at least 30 consecutive days before study drug infusion * Use of oral, patch or injectable contraceptives or a vaginal hormonal device for at least 30 consecutive days before study drug infusion * Use of a non-hormonal intrauterine device for at least 30 consecutive days before study drug infusion * Two barrier methods such as a diaphragm with spermicide or a condom with spermicide EXCLUSION CRITERIA: An individual who meets any of the following criteria prior to informed consent will be excluded from participation in this study: 1. Pregnancy or lactation. Females of childbearing potential must have a negative serum Beta-human chorionic gonadotropin test no more than 48 hours from study drug infusion. 2. A history of human immunodeficiency virus (HIV) infection. 3. History of severe drug or excipient allergy or hypersensitivity 4. Known allergy to any of the components of the investigational drug or placebo 5. Recent infection or febrile illness within the past 14 days 6. Treatment with another investigational drug within the past 30 days or 5 half-lives, whichever is longer 7. Any vaccination within the past 4 weeks or receipt of a live-attenuated vaccine within the past 6 months 8. Use of tobacco products within the past 3 months 9. Illicit drug use (e.g. cocaine, opioids, methamphetamine, PCP) within the past 6 months or positive urine drug screen at Screening Visit 10. Marijuana (cannabis) use within the past 30 days or positive urine drug screen at Screening Visit 11. History of alcohol abuse within the past 2 years 12. Current clinically significant medical illness that is uncontrolled despite appropriate medical treatment including (but not limited to) hematologic, oncologic, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, infectious, hepatic, dermatologic, psychiatric, neurologic, autoimmune or allergic disease 13. Body mass index less than 17 or greater than 32 kg/m\^2 14. Clinically significant abnormal results on clinical blood testing completed at the Screening Visit 15. Electrocardiographic evidence of clinically relevant heart disease 16. Diabetes mellitus requiring medical treatment 17. Received another monoclonal antibody in the past 30 days 18. Use of herbal supplements, or similar products within the past 2 weeks 19. Blood donation equal to or above 500 mL within 2 months prior to dosing. 20. Any other finding that, in the judgment of the Investigator, would increase the risk of having an adverse outcome from participating in the study. Justification to exclude minors: Given that the vast majority of patients with PAH are \>18 years of age and the fact that this is a first in human study, the risks of including children/minors (ie. subjects \< 18 yrs of age) are not justified given the limited potential benefits of including these subjects. Justification to exclude adults \>60 years old: Subjects \> 60 years of age are more likely to have comorbid medical conditions that could place them at increased risk of participation.
Conditions Pulmonary Hypertension
Phase Not Applicable
Enrollment 10000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to establish the large PH cohort and biological database in China, aiming for precision medicine to optimize diagnosis and treatment choices.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: pulmonary hypertension — The final outcome observed was a diagnosis of pulmonary hypertension.

Primary Outcomes

  • mean pulmonary arterial pressure (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-07-12
Completion: 2027-12-30
Eligibility
Age: 20 Years and older
Sex: ALL
Volunteers: true
Enrollment: 10000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The First Affiliated Hospital of Guangzhou Medical University
Contact Information
Study Contact:
Zili Zhang, PHD
18922269968
zhangzili_04@163.com
The First Affiliated Hospital of Guangzhou Medical University
Interventions
  • Other: pulmonary hypertension — The final outcome observed was a diagnosis of pulmonary hypertension.
Study Locations (1 sites)
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510000 China
Eligibility Criteria
Inclusion Criteria: * PH group: When the mean pulmonary artery pressure is greater than 25mmHg at rest or greater than 30mmHg during exercise. * Signed informed consent obtained prior to participations with the ability to comply with protocol and be available for study visits over 5 years. Exclusion Criteria: * Acute exacerbation in the past 3 months Having other respiratory diseases with massive lung tissue destruction such as severe bronchiectasis and tuberculosis, etc. * Serious uncontrolled diseases thoracic or abdominal surgery in the last 3 months. * Eye surgery in the last three months. * Retinal detachment myocardial infarction in the last 3 months. * Admission to hospital for any cardiac condition in the last month. * Heart rate over 120 beats per minute. * Antibacterial chemotherapy for tuberculosis pregnant or breast feeding.